A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

The first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting innovative actions, it encourages more companies to seize opportunities for change.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Big pharma' urged to develop treatments for g...
Media - published on 20 Nov 2018

Big pharma' urged to develop treatments for global health

Anne Gulland reports on how the 2018 Index found that just five firms — GSK, Johnson & Johnson, Sanofi, Merck and Novartis — are conducting two thirds of the research and development into diseases that urgently need treatments.

She notes: "GSK topped the overall list of pharmaceutical companies in terms of providing access, followed by Novartis, Johnson & Johnson and Merck. Bottom of the list of 20 global companies was the US firm Eli Lilly."

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.